




# **Your Trusted Source**

# METABOLIC RECONDITIONING

MICROBIOME TARGETED WEIGHT LOSS

**KIRAN KRISHNAN** 

Figure 5. Trends in obesity prevalence among adults aged 20 and over (age adjusted) and youth aged 2–19 years: United States, 1999–2000 through 2015–2016



## OBESITY IN THE UNITED STATES


<sup>1</sup>Significant increasing linear trend from 1999-2000 through 2015-2016.

NOTES: All estimates for adults are age adjusted by the direct method to the 2000 U.S. census population using the age groups 20-39, 40-59, and 60 and over.


Access data table for Figure 5 at: https://www.cdc.gov/nchs/data/databriefs/db288\_table.pdf#5.

SOURCE: NCHS, National Health and Nutrition Examination Survey, 1999-2016.

## 2/3 OF THE U.S. POPULATION IS OVERWEIGHT OR OBESE



Source: U.S. Census Data, CDC Data, IBIS World, MarketData Enterprises GLOBAL WEIGHT MANAGEMENT MARKET BY PRODUCT THROUGH 2014 (\$ Billions)



GLOBAL SPENDING ON WEIGHT LOSS

\$700B+ MARKET

Source: MarketsandMarkets

## U.S. Weight Loss Market is Estimated to be a \$65B per Year Industry

Total Market – \$65B Served Market – \$18B

Unserved Weight Loss \$47B


Served Weight Loss \$18B

-Diet Soft Drinks -Artificial Sweeteners -Health Club Revenues

> Source: U.S. Census Data, CDC Data, IBIS World, MarketData Enterprises

## MISSING LINK??

#### **ROLE OF THE MICROBIOME IN WEIGHT MANAGEMENT**



COMMENSAL BACTERIA THAT PROTECT AGAINST OBESITY

### Akkermansia Muciniphila:

- Mucin degrading commensal anaerobe
- Presence is inversely correlated with body weight in rodents and humans
- Increase in growth of A. muciniphila improved weight and metabolic response in Type 2 and obese mice
- Demonstrated to reverse high-fat diet induced fat-mass gain, adipose tissue inflammation and insulin resistance.
- > Effects require live, viable bacteria as heat-killed strains did not provide any effect

### Lactobacillus Species:

- Shown to reduce fat mass in mice by producing endogenous Conjugated Linoleic Acids (CLA). CLAs have been shown to induce fat burn and fat loss in animals and humans. Humans have low CLA production and are dependent on dietary sources. Commensal lactobacillus provide substantial amount of CLA from metabolism of linoleic acids.
- Dietary CLAs are mainly absorbed in the small bowel, thus most large intestine CLA must be generated by the colonic microbiota. Viable lactobacillus is a major producer of colonic CLA. This reduces inflammation and permeability that is associated with obesity

#### **COMMENSAL BACTERIA THAT PROTECT AGAINST OBESITY**

#### **Bifidobacterium Species:**

- Presence is inversely correlated with body weight in humans and animals especially B. animalis
- In mice fed a high-fat diet, viable bifidobacterium administration was shown to reduce liver triglycerides, total cholesterol, total lipid deposition and body weight gain.
- Efficient producers of CLA
- Increases the production of SCFAs and GLP-1

#### **POST-BIOTICS THAT PROTECT AGAINST OBESITY**

### SHORT-CHAIN FATTY ACIDS (BUTYRATE, ACETATE and PROPRIONATE):

- Increased production of butyrate and acetate are associated with leaner body mass
- SCFAs act as signaling molecules that interact with the G-protein-coupled receptors, Gpr41 and Gpr43, expressed on adipocytes and intestinal epithelium Gpr41 activation by SCFAs stimulates leptin production which reduces appetite.
- Adipocytes sense intestinal SCFA production and release adiponectin in response. Adiponectin is associated with an up-regulation of AMPK, which is an enzyme that monitors cellular energy status and stimulates fatty acid oxidation in peripheral tissues.
- In obesity, low SCFAs are produced, thereby less adiponectin is generated and AMPK which dramatically decreases fatty acid oxidation and an increased influx of free fatty acids into the liver – NAFLD is associated with obesity.

#### INTESTINAL DYSFUNCTIONS THAT PLAY A CAUSAL ROLE IN OBESITY

### **METABOLIC ENDOTOXEMIA:**

- Characterized by a sharp increase in serum LPS levels post-prandial
- Post-prandial endotoxemia is followed by TLR4-CD14 immune activation and chronic, low grade inflammation.
- Metabolic endotoxemia is associated with a dysbiotic microbiota and is caused by a dysfunctional intestinal barrier.
- Metabolic endotoxemia induces obesity and diabetes
- Increased circulating LPS causes insulin resistance via hypothalamic JNK expression (inflammation) irrespective of body weight
- LPS causes morphological changes and swelling of adipocytes
- LPS disrupts the function of the enteric nervous system and causes leptin resistance by disrupting metabolic signals from the gut to the brain



**Obesity Studies** 

### Metabolic Endotoxemia Initiates Obesity and Insulin Resistance

Patrice D. Cani12, Jacques Amar3, Miguel Angel Iglesias1, Marjorie Poggi4, Claude Knauf1, Delphine Bastelica4, Audrey M. Neyrinck2, Francesca Fava5, Kieran M. Tuohy5, Chantal Chabo1, Aurélie Waget1, Evelyne Delmée2, Béatrice Cousin6, Thierry Sulpice7, Bernard Chamontin3, Jean Ferrières3, Jean-François Tanti8, Glenn R. Gibson5, Louis Casteilla6, Nathalie M. Delzenne2, Marie Christine Alessi4 **and** Rémy Burcelin1

+ Author Affiliations

Address correspondence and reprint requests to Rémy Burcelin, I2MR U858, IFR 31, Hôpital Rangueil, BP 84225, Toulouse 31432 Cedex 4, France. E-mail: burcelin@toulouse.inserm.fr

Diabetes 2007 Jul; 56(7): 1761-1772. https://doi.org/10.2337/db06-1491

### **OBESITY IS ASSOCIATED WITH:**

LOW LEVELS OF BIFIDOBACTERIA SP.
LOW LEVELS OF A. MUCINIPHILA
LOW LEVELS OF CERTAIN POST-BIOTICS – SCFAs, CLAs, etc.
HIGH LEVELS OF METABOLIC ENDOTOXEMIA

#### **MICROBIOME TARGETED WEIGHT LOSS**

- INCREASING ENDOGENOUS LEVELS OF BIFIDOBACTERIA SP.
- INCREASING ENDOGENOUS LEVELS OF A. MUCINIPHILA
- INCREASING SCFA PRODUCTION
- REDUCING OR ALEVIATING METABOLIC ENDOTOXEMIA

AIDP AND MICROBIOME LABS HAVE COLLABORATED TO DEVELOP A MICROBIOME FOCUSED WEIGHT MANAGEMENT SOLUTION BY UTILIZING THE POWER OF SYNBIOTICS






MICROBIOME TARGETED WEIGHT LOSS


**PRETICX (XYLOOLIGOSACCHARIED) + SPORE-BASED PROBIOTICS** 





#### Figure1: PreticX increases Bifidobacterial as low as 1.4g/day

A: UCLA study (Dr. Li and Dr. Heber, et al Food Funct., 2014, 5, 436)



5g XOS supplementation leads to a switch of Acetate to

J. Lecerf, et.al. British Journal of Nutrition (2012), 108, 1847–1858




# Propionate and Butyric production in Human

Sample Footer Text

SCFA production profile of Different Prebiotics in Animal Model of Constipation

KunMing Mice: 14 days of Supplementation at 2.0g/kg BW



Optimize Your Flora



Submit a Manuscript: http://www.f6publishing.com

World J Gastrointest Pathophysiol 2017 August 15; 8(3): 117-126

DOI: 10.4291/wjgp.v8.i3.117

ISSN 2150-5330 (online)

ORIGINAL ARTICLE

#### **Prospective Study**

Oral spore-based probiotic supplementation was associated with reduced incidence of post-prandial dietary endotoxin, triglycerides, and disease risk biomarkers

#### Brian K McFarlin, Andrea L Henning, Erin M Bowman, Melody M Gary, Kimberly M Carbajal

Brian K McFarlin, Andrea L Henning, Erin M Bowman, Melody M Gary, Applied Physiology Laboratory, University of North Texas, Denton, TX 76203, United States

Brian K McFarlin, Andrea L Henning, Kimberly M Carbajal, Department of Biological Sciences, University of North Texas, Denton, TX 76203, United States

Author contributions: McFarlin BK designed the study, collected data, interrupted findings, and prepared manuscript; Henning AL, Bowman EM, Gary MM and Carbajal KM collected data, interrupted findings, and prepared manuscript.

Institutional review board statement: The study was reviewed

#### licenses/by-nc/4.0/


Manuscript source: Invited manuscript

Correspondence to: Brian K McFarlin, PhD, FACSM, FTOS, Associate Professor, Applied Physiology Laboratory, University of North Texas, 1921 West Chestnut Street, PEB Room 209, Denton, TX 76203, United States. <u>brian.mcfarlin@unt.edu</u> Telephone: +1-940-5653165 Fax: +1-940-5654904

Received: January 26, 2017 Peer-review started: February 8, 2017 First decision: April 17, 2017


## METABOLIC ENDOTOXEMIA

The effect of 30-days of probiotic supplementation on post-prandial responses to a high-fat meal: Pilot Study Principal Investigator: Brian K. McFarlin, PhD, FACSM, FTOS University of NorthTexas




UNIVERSITY OF NORTH\*TEXAS The effect of 30-days of probiotic supplementation on post-prandial responses to a high-fat meal: Pilot Study Principal Investigator: Brian K. McFarlin, PhD, FACSM, FTOS University of NorthTexas





The effect of 30-days of probiotic supplementation on post-prandial responses to a high-fat meal: Pilot Study Principal Investigator: Brian K. McFarlin, PhD, FACSM, FTOS University of North Texas













PRELIMINARY TRIAL ON THE XOS + BACILLUS ENDOSPORE SYNBIOTIC











The Effect of 90-days of Fiber/Probiotic Supplementation on Body Composition and Weight Management in Overweight Individuals


> Principal Investigator: Brian K. McFarlin, PhD, FACSM, FTOS Associate Professor Department of Kinesiology, Health Promotion and

## SAMPLE RESULTS

After 90-d:

- 4 kg increase in lean mass
- ~1.5 kg drop in fat mass
- % Fat dropped from 43% to 41%.

# NO DIET CHANGES, EXERCISE OR ANY LIFESTYLE MODIFICATION.



## MICROBIOME TARGETED WEIGHT LOSS WITH A SYNBIOTIC (XOS AND SPORES)

## **THIS UNIQUE SYNBIOTIC:**

- INCREASES ENDOGENOUS LEVELS OF BIFIDOBACTERIA SP.
- INCREASES ENDOGENOUS LEVELS OF A. MUCINIPHILA
- INCREASES SCFA PRODUCTION
- REDUCES METABOLIC ENDOTOXEMIA
- ALLOWS FOR STEADY FAT LOSS AND INCREASE IN LEAN MUSCLE MASS EVEN WITHOUT DIET OR EXERCISE
- AS PART OF A HEALTHY WEIGHT MANAGEMENT PROGRAM, THIS SYNBIOTIC COULD DRAMATICALLY IMPROVE RESULTS





